Zealand Pharma
ZEAL
Performance
About Zealand Pharma
Zealand Pharma is an international biotechnology company based in Denmark with operations in Boston, USA, focused on discovering, designing, and developing innovative peptide-based medicines and small molecule therapies that address unmet medical needs. The company concentrates on metabolic health and diseases where peptide therapeutics can transform outcomes, including obesity, congenital hyperinsulinism, short bowel syndrome, and chronic inflammation. Zealand aims to build a leading metabolic health pipeline with a portfolio of differentiated candidates and a commitment to advancing patient care globally. Its activities span research, development, and collaborations to bring novel treatments to patients in both Europe and North America.
Recent News
Roche Insists Amylin Obesity Drug Still Valuable for Patients Who ‘Don’t Want Side Effects’
Biotech in 2025: A Retrospective
Zealand Pharma and Roche Advance Petrelintide to Phase 3 for Chronic Weight Management
Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Boosting Obesity Drug Race
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Boehringer, Zealand’s Obesity Drug ‘More Akin’ to Novo’s Wegovy in Phase 3
Roche, Facing Biosimilar Threats, Puts Faith in New Cancer and Obesity Drugs
The BioPharm Brief: Metabolic Phase III Progress, HER2 Oncology Momentum, and US Manufacturing Expansion Drive Industry Scale
10 Obesity Drug Companies to Watch in 2026
Roche Q1 Sales Slip 5% to $18.7B as Swiss Franc Gains Offset Drug Gains
Roche Claims Midstage Win for Obesity Injectable
Cardiometabolic Intervention: Evaluation of PCSK9 Inhibitors as the Successor to the GLP-1 Phenomenon
Swiss Franc Strength Puts Roche's Results in a Poor Light
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche and Zealand Pharma Report P-II (ZUPREME-1) Trial Data on Petrelintide in Obesity
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
Recent Deals
No recent deals for this company.